Liver enzyme levels in adolescent patients treated with buprenorphine and additional psychotropic agents

References

• Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the future: national results on adolescent drug use: overview of key findings, 2010. Ann Arbor, MI: Institute for Social Research, The University of Michigan, 2011
   Google Scholar
• Bilici R, Karakas Ugurlu G, Tufan E, Guven T, Ugurlu M. The Sociodemographic Features of Patients Hospitalized at a Center For Addiction. Fırat Med J 2012;17:223–227
   Google Scholar
• United Nations Office of Drugs and Crime (UNODC). World Drug Report 2013. Vienna, Austria: UNODC; 2013. Available from: http://www.unodc.org/unodc/secured/wdr/wdr2013/World%20_Drug_Report_2013.pdf, last accessed 30 May 2014
   Google Scholar
• Gowing L, Ali R, White JM. Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 2009;3:CD002025
   Google Scholar
• Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005;28:321–329
   PubMed Web of Science ®Google Scholar
• Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2004;3:CD002207
   Google Scholar
• Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, Brooklyn J. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry 2005;62:1157–1164
   PubMed Web of Science ®Google Scholar
• Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, Patkar A, et al. Extended vs. short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA 2008;300:2003–2011
   PubMed Web of Science ®Google Scholar
• Houdret N, Asnar V, Szostak-Talbodec N, Leteurtre E, Humbert L, Lecomte-Houcke M, Lhermitte M, Paris JC. Hepatonephritis and massive ingestion of buprenorphine. Acta Clin Belg Suppl 1999;1:29–31
   Google Scholar
• Berson A, Gervais A, Cazals D, Boyer N, Durand F, Bernuau J, Marcellin P, et al. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol 2001;34:346–350
   PubMed Web of Science ®Google Scholar
• Hervé S, Riachi G, Noblet C, Guillement N, Tanasescu S, Goria O, Thuillez C, et al. Acute hepatitis due to buprenorphine administration. Eur J Gastroenterol Hepatol 2004;16:1033–1037
   PubMed Web of Science ®Google Scholar
• Zuin M, Giorgini A, Selmi C, Battezzati PM, Cocchi CA, Crosignani A, Benetti A, et al. Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. Dig Liver Dis 2009;41:e8–10
   PubMedGoogle Scholar
• Saxon AJ, Ling W, Hillhouse M, Thomas C, Hasson A, Ang A, Doraimani G, et al. Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend 2013;128:71–76
   PubMed Web of Science ®Google Scholar
• Bogenschutz MP, Abbott PJ, Kushner R, Tonigan JS, Woody GE. Effects of buprenorphine and hepatitis C on liver enzymes in adolescents and young adults. J Addict Med 2010;4:211–216
   Google Scholar
• Peyriere H, Tatern L, Bories C, Pageua GP, Blayac JP, Larrey D. Hepatitis after intravenous injection of sublingual buprenorphine in acute hepatitis C carriers: report of two cases of disappearance of viral replication after acute hepatitis. Ann Pharmacother 2009;43:973–977
   Google Scholar
• Petry NM, Bickel WK, Piasecki D, Marsch LA, Badger GJ. Elevated liver enzyme levels in opioid dependent patients with hepatitis treated with buprenorphine. Am J Addict 2000;9:265–269
   PubMed Web of Science ®Google Scholar
• Nordfjaern T. Prevalence of substance use and mental distress among patients on waiting lists for substance use disorder treatment. J Psychoactive Drugs 2013;45:233–240
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press; 1994
   Google Scholar
• Berson A, Fau D, Fornacciari R, Degove-Goddard P, Sutton A, Descatoire V, Haouzi D, et al. Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J Hepatol 2001;34:261–269
   PubMed Web of Science ®Google Scholar
• Teschke R, Wolff A, Frenzel C, Schwarzenboeck A, Schulze J, Eickhoff A. Drug and herb induced liver injury: Council for International Organizations of Medical Sciences scale for causality assessment. World J Hepatol 2014;6:17–32
   PubMedGoogle Scholar
• Upadhyay A, Xueming Y. Buprenorphine-induced elevated liver enzymes in an adolescent patient. J Child Adolesc Psychopharmacol 2010;20:545–546
   Google Scholar
• Erdogan A, Atasoy N, Akkurt H, Ozturk D, Karaahmet E, Yalug I, Yalug K, et al. Risperidone and liver function tests in children and adolescents: a short-term prospective study. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:849–857
   PubMed Web of Science ®Google Scholar
• Szigethy E, Wiznitzer M, Branicky LA, Maxwell K, Findling RL. Risperidone-induced hepatotoxicity in children and adolescents? A chart review study. J Child Adolesc Psychopharmacol 1999;9:93–98
   PubMedGoogle Scholar
• Kumra S, Herion D, Jacobsen LK, Briguglia C, Grothe D. Case study: risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry 1997;36:701–705
   PubMed Web of Science ®Google Scholar
• Dumortier G, Cabaret W, Stamatiadis L, Saba G, Benadhira R, Rocamora JF, Aubriot-Delmas B, et al. Hepatic tolerance of atypical antipsychotic drugs. Encephale 2002;28:542–551
   PubMed Web of Science ®Google Scholar
• Shpaner A, Li W, Ankoma-Sey V, Botero RC. Drug-induced liver injury: hepatotoxicity of quetiapine revisited. Eur J Gastroenterol Hepatol 2008;20:1106–1109
   PubMed Web of Science ®Google Scholar
• Bruce RD, Altice FL. Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases. Am J Drug Alcohol Abuse 2007;33:869–874
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther 1994;55:569–580
   PubMed Web of Science ®Google Scholar
• Peyrière H, Tatem L, Bories C, Pageaux GP, Blayac JP, Larrey D. Hepatitis after intravenous injection of sublingual buprenorphine in acute hepatitis C carriers: report of two cases of disappearance of viral replication after acute hepatitis. Ann Pharmacother 2009;43:973–977
   Google Scholar
• Tegeder I, Lötsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999;37:17–40
   PubMed Web of Science ®Google Scholar
• Swift W, Williams G, Neill O, Grenyer B. The prevalence of minor psychopathology in opioid users seeking treatment. Br J Addict 1990;85:629–634. Eur Addict Res 2012;18:253–264
   PubMedGoogle Scholar
• Havassy BE, Alvidrez J, Owen KK. Comparisons of patients with comorbid psychiatric and substance use disorders: implications for treatment and service delivery. Am J Psychiatry 2004;161:139–145
   PubMed Web of Science ®Google Scholar
• Voican CS, Corruble E, Naveau S, Perlemuter G. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry 2014;171:404–415
   PubMed Web of Science ®Google Scholar
• Lewis JJ, Iezzoni JC, Berg CL. Methylphenidate-induced autoimmune hepatitis. Dig Dis Sci 2007;52:594–597
   PubMed Web of Science ®Google Scholar
• Bangs ME, Jin L, Zhang S, Desaiah D, Allen AJ, Read HA, Regev A, Wernicke JF. Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder. Drug Saf 2008;31:345–354
   PubMed Web of Science ®Google Scholar
• Spahr L, Coeytaux A, Giostra E, Hadengue A, Annoni JM. Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial. Am J Gastroenterol 2007;102:744–753
   PubMed Web of Science ®Google Scholar
• Gómez-Lechón MJ, Ponsoda X, Jover R, Fabra R, Trullenque R, Castell JV. Hepatotoxicity of the opioids morphine, heroin, meperidine, and methadone to cultured human hepatocytes. Mol Toxicol 1987–1988;1:453–463
   PubMedGoogle Scholar
• Dennhardt AA, Murphy JG. Prevention and treatment of college student drug use: a review of the literature. Addict Behav 2013;38:2607–2618
   PubMed Web of Science ®Google Scholar